Company Report

Company Reports / Sanofi

COMPANY: Sanofi

INDEX RANK: 1st

Total Impact Score: 18,633,104.44

Sanofi is ranked 1st place in our index for 2015. Sanofi’s drugs have a total impact score of 18,633,104.44. Sanofi treats three diseases in our model - P. falc malaria, P. vivax malaria, and DS-TB - with seven total drugs - RIfampicin (R or RMP), Artesunate/Amodiaquine (AS + AQ), Artesunate / Sulfadoxine-pyrimethamine (AS + SP), Chloroquine + Primaquine (CQ + PQ), Artesunate + Mefloquine + Primaquine (AS + MQ + PQ), Artesunate + Amodiaquine + Primaquine (AS + AQ + PQ), and Artesunate + Sulfadoxine + Primaquine (AS + SP + PQ). Sanofi receives credit for five treatments against P. falc malaria - Artesunate/Amodiaquine (AS + AQ), Artesunate + Sulfadoxine + Primaquine (AS + SP + PQ), Artesunate / Sulfadoxine-pyrimethamine (AS + SP), Artesunate + Mefloquine + Primaquine (AS + MQ + PQ), and Chloroquine + Primaquine (CQ + PQ). These five drugs averted 9,792,177.01 of the total DALYS for P. falc malaria, which is 43.05% of the worldwide DALYs that we estimate would have been lost due to P. falc malaria in 2015 in the absence of effective treatment. Sanofi’s drug portfolio placed it 2nd in terms of total averted DALYs for P. falc malaria. Sanofi receives credit for two treatments against P. vivax malaria - Chloroquine + Primaquine (CQ + PQ) and Artesunate + Amodiaquine + Primaquine (AS + AQ + PQ). These two drugs averted 370,800.53 of the total DALYS for P. vivax malaria, which is 95.08% of the worldwide DALYs that we estimate would have been lost due to P. vivax malaria in 2015 in the absence of effective treatment. Sanofi’s drug portfolio placed it 1st in terms of total averted DALYs for P. vivax malaria. Sanofi receives credit for one treatment against DS-TB - RIfampicin (R or RMP). This one drug averted 8,470,126.91 of the total DALYS for DS-TB, which is 25.00% of the worldwide DALYs that we estimate would have been lost due to DS-TB in 2015 in the absence of effective treatment. Sanofi’s drug portfolio placed it in a tie for 1st in terms of total averted DALYs for DS-TB.

Company Score Breakdown:

Key Drugs

ARTESUNATE-SULFADOXINEPYRIMETHAMINE (AS+SP)

Artesunate-Sulfadoxine-Pyrimethamine (AS+SP) is an artemisinin-based combination therapy recommended by the WHO as one of the primary treatments for both uncomplicated and severe malaria. It is generally as safe and effective AS+AQ, but resistance to this combination significantly reduces its efficacy in the treatment of Plasmodium vivax (P. vivax) malaria. Hoechst, which later became a part of Sanofi, filed a patent for AS+AP in 1988.

ARTESUNATE+AMODIAQUINE(AS+AQ)

Artesunate+Amodiaquine (AS+AQ) is an artemisinin-based combination therapy (ACT) recommended by the WHO as one of the primary treatments for both uncomplicated and severe malaria. It is relatively safe and effective with the recommended dosing and 3-day duration. The first patent for AS+AQ was filed in 1988 by Hoechst which is now a part of Sanofi.

Company Information

Sanofi is a global pharmaceutical company founded in 1973, headquartered in Paris, France, and formed from the mergers of several companies between 1999 and 2011. Their products fall into several therapeutic areas including: cardiovascular, anti-infection, diabetes, immunology, neurology, oncology, rare disease and general well-being (nutrition, pain, allergy). A few of their key products include Ambien®, Plavix®, Renagel®, and the vaccines, Fluzone® and Menactra®. In their effort to reduce the global disease burden Sanofi has: collaborated with the Drugs for Neglected Diseases Initiative to create the ASAQ Winthrop®, an anti-malaria drug that has enabled the treatment of over 450 million cases at preferential pricing since 2007, worked with national malaria control programs and various NGOs to develop the Schoolchildren against Malaria Program aimed at promoting prevention behavior in schools in Africa, and is currently running a clinical trial, in collaboration with the Medicines for Malaria Venture, to develop Ferroquine, a potential alternative to artemisinin-based treatments that are being increasingly resisted. In 2017, Sanofi reported $40.9 billion dollars in revenue and 100,000 employees in 100 countries.

Company Report PDF